Clinical Trial Update: The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and efficacy of ibrutinib in patients with refractory or relapsed autoimmune hemolytic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING